400771-42-8 Usage
General Description
The chemical (2-methoxy-5-(trifluoromethyl)phenyl)methanamine, also known as methoxytrifluoromethylphenylmethanamine, is a compound that belongs to the class of amines. It is characterized by the presence of a methoxy group and a trifluoromethyl group attached to a phenyl ring, with the amine functional group at the other end of the molecule. (2-methoxy-5-(trifluoromethyl)phenyl)methanamine may have applications in organic synthesis, pharmaceutical research, and material science due to its unique structure and properties. It is important to handle and use this chemical with care, following proper safety protocols and procedures to avoid any potential hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 400771-42-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,0,7,7 and 1 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 400771-42:
(8*4)+(7*0)+(6*0)+(5*7)+(4*7)+(3*1)+(2*4)+(1*2)=108
108 % 10 = 8
So 400771-42-8 is a valid CAS Registry Number.
400771-42-8Relevant articles and documents
HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY
-
Paragraph 0121; 0122, (2017/06/23)
The invention relates to HDAC inhibitors for use in the treatment of diabetic peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor.
GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
-
Page/Page column 119, (2010/02/13)
The invention relates to guanidine compounds of general formula (I), corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and pharmaceutically acceptable salts thereof. The invention further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors in order to treat diseases modulated by 5-HT5 receptor activity, especially treat neurodegenerative and neuropsychiatric disorders and the signs, symptoms, and malfunctions associated therewith.
